



Atty. Dkt. No.	M#	Client Ref.
	0275537	1998-30-0524A
Applicant: GRILLO-LOPEZ et al.		
Appln. No.: 09/436,348		
Filing Date: November 9, 1999		
Examiner: R. Schwadron		Group Art Unit: 1644

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: October 24, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 5,530,101	06/1996	Queen et al.			
	BR 5,225,539	07/1993	Winter et al.			
	CR 4,816,397	03/1989	Boss et al.			
	DR 4,816,567	03/1989	Cabilly et al.			
	ER 5,500,362	03/1996	Robinson et al.			
	FR 5,736,137	04/1988	Anderson et al.			
	GR 6,183,744	02/2001	Goldenberg			
	HR 6,306,393	10/2001	Goldenberg			
	IR					
	JR					
	KR					
	LR					
	MR					
	NR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
	OR									
	PR									
	QR									
	RR									
	SR									
	TR									
	UR									
	VR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

WR	McLaughlin et al., Rituximab® chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program, (1998), <i>J Clin Oncology</i> , 16:2825-2833.
XR	McLaughlin et al., Efficacy controls in long-term follow-up patients treated with rituximab for relapsed or refractory, low-grade or follicular NHL, (1998), <i>Blood</i> , 92:414a-415a.
YR	Janakiraman et al., Rituximab: Correlation between effector cells and clinical activity in NHL, (1998), <i>Blood</i> , 92(10 suppl 1):337a.
ZR	Rottenburger et al., Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation, (1999), <i>Br J Haematol.</i> , 106(2):545-552.

Examiner: _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DO NOT
consider
12/25/2003